BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30963412)

  • 1. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
    Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
    Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
    Packer LM; Stehbens SJ; Bonazzi VF; Gunter JH; Ju RJ; Ward M; Gartside MG; Byron SA; Pollock PM
    Mol Oncol; 2019 Apr; 13(4):738-756. PubMed ID: 30537101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
    Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
    Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells.
    Taniguchi F; Harada T; Sakamoto Y; Yamauchi N; Yoshida S; Iwabe T; Terakawa N
    J Clin Endocrinol Metab; 2003 Feb; 88(2):773-80. PubMed ID: 12574212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
    Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
    Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of N-[N-(3, 5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) on cell proliferation and apoptosis in Ishikawa endometrial cancer cells.
    Mori M; Miyamoto T; Yakushiji H; Ohno S; Miyake Y; Sakaguchi T; Hattori M; Hongo A; Nakaizumi A; Ueda M; Ohno E
    Hum Cell; 2012 Mar; 25(1):9-15. PubMed ID: 22189483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor Receptor Signaling in Skin Cancers.
    Czyz M
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.
    Dixit G; Gonzalez-Bosquet J; Skurski J; Devor EJ; Dickerson EB; Nothnick WB; Issuree PD; Leslie KK; Maretzky T
    Clin Transl Med; 2023 May; 13(5):e1223. PubMed ID: 37165578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
    André F; Cortés J
    Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
    Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
    Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
    Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
    Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling.
    Guo Q; Qian Z; Yan D; Li L; Huang L
    Biomed Pharmacother; 2016 Aug; 82():589-94. PubMed ID: 27470401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-2 stimulates proliferation of human adipose-derived stem cells via Src activation.
    Ma Y; Kakudo N; Morimoto N; Lai F; Taketani S; Kusumoto K
    Stem Cell Res Ther; 2019 Nov; 10(1):350. PubMed ID: 31775870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.
    Stehbens SJ; Ju RJ; Adams MN; Perry SR; Haass NK; Bryant DM; Pollock PM
    J Cell Sci; 2018 Aug; 131(15):. PubMed ID: 30002137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.